U.S. markets closed
  • S&P 500

    4,566.48
    +21.58 (+0.47%)
     
  • Dow 30

    35,741.15
    +64.13 (+0.18%)
     
  • Nasdaq

    15,226.71
    +136.51 (+0.90%)
     
  • Russell 2000

    2,312.64
    +21.37 (+0.93%)
     
  • Crude Oil

    83.71
    -0.05 (-0.06%)
     
  • Gold

    1,809.20
    +2.40 (+0.13%)
     
  • Silver

    24.62
    +0.03 (+0.11%)
     
  • EUR/USD

    1.1612
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.6350
    -0.0200 (-1.21%)
     
  • GBP/USD

    1.3763
    -0.0006 (-0.04%)
     
  • USD/JPY

    113.7090
    +0.0100 (+0.01%)
     
  • BTC-USD

    62,985.18
    +2,144.32 (+3.52%)
     
  • CMC Crypto 200

    1,502.82
    +1,260.14 (+519.26%)
     
  • FTSE 100

    7,222.82
    +18.27 (+0.25%)
     
  • Nikkei 225

    28,600.41
    -204.44 (-0.71%)
     

Buying This Beaten-Down ETF Could Double Your Money Over the Next 5 Years

·4 min read
Buying This Beaten-Down ETF Could Double Your Money Over the Next 5 Years
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

The iShares Biotechnology ETF (NASDAQ: IBB) has delivered a solid double-digit percentage gain. Meanwhile, the SPDR S&P Biotech ETF (NYSEMKT: XBI) is in negative territory year to date and is close to 25% below its February highs. The key to success for the iShares Biotechnology ETF (IBB) has been Moderna (NASDAQ: MRNA).